CA3020348A1 - Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents - Google Patents
Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents Download PDFInfo
- Publication number
- CA3020348A1 CA3020348A1 CA3020348A CA3020348A CA3020348A1 CA 3020348 A1 CA3020348 A1 CA 3020348A1 CA 3020348 A CA3020348 A CA 3020348A CA 3020348 A CA3020348 A CA 3020348A CA 3020348 A1 CA3020348 A1 CA 3020348A1
- Authority
- CA
- Canada
- Prior art keywords
- cancer
- compound
- chosen
- acetyl
- propiolyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
- C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/36—Oxygen or sulfur atoms
- C07D207/40—2,5-Pyrrolidine-diones
- C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
- C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
- C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662320654P | 2016-04-11 | 2016-04-11 | |
| US62/320,654 | 2016-04-11 | ||
| PCT/CA2017/050432 WO2017177316A1 (en) | 2016-04-11 | 2017-04-10 | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3020348A1 true CA3020348A1 (en) | 2017-10-19 |
Family
ID=60041299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3020348A Abandoned CA3020348A1 (en) | 2016-04-11 | 2017-04-10 | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US10759754B2 (https=) |
| EP (1) | EP3442943B1 (https=) |
| JP (1) | JP2019513829A (https=) |
| CN (1) | CN109071433A (https=) |
| CA (1) | CA3020348A1 (https=) |
| WO (1) | WO2017177316A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10787701B2 (en) | 2010-04-05 | 2020-09-29 | Prognosys Biosciences, Inc. | Spatially encoded biological assays |
| EP3013983B1 (en) | 2013-06-25 | 2023-02-15 | Prognosys Biosciences, Inc. | Spatially encoded biological assays using a microfluidic device |
| SG11202006246PA (en) | 2018-01-17 | 2020-07-29 | Aurigene Discovery Tech Ltd | Substituted alkynylene compounds as anticancer agents |
| CA3021417A1 (en) * | 2018-10-18 | 2020-04-18 | 3R Valo, S.E.C. | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents |
| CN114516819B (zh) * | 2022-02-25 | 2024-02-27 | 顺毅宜昌化工有限公司 | 一种n,n’-二乙酰基肼的制备方法 |
| CN117447353B (zh) * | 2023-09-21 | 2025-12-30 | 爱斯特（成都）生物制药股份有限公司 | 一种氘可来昔替尼中间体的制备方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3046301A (en) | 1959-10-29 | 1962-07-24 | Burroughs Wellcome Co | Method of making chlorambucil |
| US20060235034A1 (en) * | 2004-11-01 | 2006-10-19 | Nouri Neamati | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| US11384104B2 (en) * | 2015-06-19 | 2022-07-12 | Centurion Biopharma Corporation | Delivery systems for controlled drug release |
-
2017
- 2017-04-10 JP JP2019503603A patent/JP2019513829A/ja not_active Ceased
- 2017-04-10 WO PCT/CA2017/050432 patent/WO2017177316A1/en not_active Ceased
- 2017-04-10 US US16/091,721 patent/US10759754B2/en not_active Expired - Fee Related
- 2017-04-10 EP EP17781669.1A patent/EP3442943B1/en not_active Not-in-force
- 2017-04-10 CA CA3020348A patent/CA3020348A1/en not_active Abandoned
- 2017-04-10 CN CN201780022811.3A patent/CN109071433A/zh active Pending
-
2020
- 2020-08-07 US US16/988,332 patent/US20210002222A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109071433A (zh) | 2018-12-21 |
| EP3442943A4 (en) | 2019-03-20 |
| JP2019513829A (ja) | 2019-05-30 |
| EP3442943A1 (en) | 2019-02-20 |
| US10759754B2 (en) | 2020-09-01 |
| WO2017177316A1 (en) | 2017-10-19 |
| US20210002222A1 (en) | 2021-01-07 |
| US20190127325A1 (en) | 2019-05-02 |
| EP3442943B1 (en) | 2020-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3442943B1 (en) | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents | |
| ES2640003T3 (es) | Productos terapéuticos derivados de éter diglicidílico y métodos para su uso | |
| US12448372B2 (en) | Class of triaromatic compounds targeting bifunctional phosphorylation site of STAT3 and applications thereof | |
| ES3051007T3 (en) | Farnesoid x receptor agonists and uses thereof | |
| JP2020090553A (ja) | Ｅ−セレクチンおよびｃｘｃｒ４ケモカイン受容体のヘテロ二官能性阻害剤 | |
| WO2022268025A1 (zh) | Atr抑制剂及其用途 | |
| KR102338568B1 (ko) | 퀴나졸린 유도체 | |
| KR102343865B1 (ko) | Yap-tead 결합을 저해하는 화합물 및 이를 유효 성분으로 함유하는 암의 예방 또는 치료용 약제학적 조성물 | |
| CN111566113B (zh) | 大环化合物及其用途 | |
| Hamelin-Morrissette et al. | Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of its structural components on inflammatory responses in macrophages and bladder cancer cells | |
| CN104603133B (zh) | 用于治疗癌症和免疫抑制的组合疗法 | |
| CA2926928A1 (en) | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents | |
| CA3021417A1 (en) | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents | |
| JP2023550402A (ja) | ビグアニジンの二量体及びその治療的使用 | |
| BRPI0906248B1 (pt) | composto, composição farmacêutica para inibir a formação de microtúbulos e método para preparar um composto | |
| CN106995368B (zh) | 一种非atp竞争性fgfr1抑制剂及其应用 | |
| CN114026098B (zh) | 苯并吡喃基化合物、方法及其用途 | |
| CN111170980B (zh) | 一种毛蕊异黄酮衍生物及其合成方法和应用 | |
| HK40001514A (en) | Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents | |
| AU2017380492A1 (en) | Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof | |
| CN107011266B (zh) | 苯并吲唑类衍生物的前药及其制备方法、应用 | |
| JP6082488B1 (ja) | カルボキシル基により酸性になったｐａｋ１遮断剤のエステル体の調製および癌やその他のｐａｋ１依存性疾患治療への応用 | |
| RU2527526C2 (ru) | Индолил-замещенные пиразино-хинолины и их применение для лечения рака | |
| JP2021529782A (ja) | 新生物障害及び神経性障害の診断、治療及び予防のための組成物及び方法 | |
| CN103374001B (zh) | 咪唑并三嗪类mTOR抑制剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220410 |
|
| FZDE | Discontinued |
Effective date: 20230920 |